Hemab Therapeutics Holdings Acquisition | Healthcare Deal in MA

Hemab Therapeutics Holdings has completed the acquisition of Hemab Therapeutics Holdings, a healthcare services other business in Massachusetts, for $346.7 million. Hemab Therapeutics Holdings is a clinical-stage biotechnology company developing therapies for blood coagulation disorders, supporting healthcare services other needs in MA. The company’s initial public offering proceeds were driven by a $18.00 per share pricing and full exercise of underwriters’ option to purchase additional shares, expanding MA healthcare M&A capacity. The healthcare deals MA structure was an other acquisition-style capital raise by a strategic public company, with gross proceeds of approximately $346.7 million and Nasdaq Global Select Market trading under ticker COAG.